ReviewFrontiers in cellular neuroscience2017
Microglia: An Interface between the Loss of Neuroplasticity and Depression.
Review in Frontiers in cellular neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 223 citations in OpenAlex.
- High plasma levels of soluble triggering receptor expressed on Myeloid Cells 2 were associated with depression in patients with newly diagnosed type 2 diabetes mellitus.Journal of clinical & translational endocrinology · 2026Article
- Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026Article
- Feasibility of diagnosing major depressive disorder with a panel of serum and urine biomarkers.BJPsych open · 2026Article
- IL-33-induced neuroimmune regulation in depression: A narrative review from molecular mechanisms to therapeutic potential.Medicine · 2026Review
- Clinical and biological markers of electroconvulsive therapy effectiveness: a narrative review.Translational psychiatry · 2026Review
- Dynamic regulation and targeted interventions of macrophages in ischemia-reperfusion injury.Journal of advanced research · 2026Review
- Disodium Cromoglycate Attenuates the Depressive-Like Behaviors in Mice by Inhibiting Neuroinflammation.CNS neuroscience & therapeutics · 2026Article
- How three different theories of depression converge at inflammation.Discover mental health · 2025Review
- Role of astrocyte in neuroinflammation-induced loss in neuroplasticity and subsequent onset of depression: A systematic review.Neuroprotection (Chichester, England) · 2025Review
- Article
- Microglia Single-Cell RNA-Seq Enables Robust and Applicable Markers of Biological Aging.Aging cell · 2025Article
- Unveiling the Anti-Inflammatory Effects of Antidepressants: A Systematic Review of Human Studies over the Last Decade.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Associations of dietary and plasma lutein + zeaxanthin with depression in US adults: findings from NHANES.Asia Pacific journal of clinical nutrition · 2025Article
- Neuroinflammation-A Crucial Factor in the Pathophysiology of Depression-A Comprehensive Review.Biomolecules · 2025Review
- Magnetic resonance imaging signatures of neuroinflammation in major depressive disorder with religious and spiritual problems.Scientific reports · 2025Article
- A Bibliometric Analysis of Research on Natural Medicines for Depression from 2004 to 2024.Journal of multidisciplinary healthcare · 2025Article
- Hypothyroidism Promotes Microglia M1 Polarization by Inhibiting BDNF-Promoted PI3K-Akt Signaling Pathway.Neuroendocrinology · 2025Article
- Transcutaneous auricular vagus nerve stimulation alleviates inflammation-induced depression by modulating peripheral-central inflammatory cytokines and the NF-κB pathway in rats.Frontiers in immunology · 2025Article
- Leveraging Single-Cell RNA-Seq to Generate Robust Microglia Aging Clocks.bioRxiv : the preprint server for biology · 2024Article
- Fructus Arctii Mitigates Depressive Disorder via the Let-7e-Modulated Toll-Like Receptor (TLR) Signaling Pathway.Brain and behavior · 2024Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression has been widely accepted as a major psychiatric disease affecting nearly 350 million people worldwide. Research focus is now shifting from studying the extrinsic and social factors of depression to the underlying molecular causes. Microglial activity is shown to be associated with pathological conditions, such as psychological stress, pathological aging, and chronic infections. These are primary immune effector cells in the CNS and regulate the extensive dialogue between the nervous and the immune systems in response to different immunological, physiological, and psychological stressors. Studies have suggested that during stress and pathologies, microglia play a significant role in the disruption of neuroplasticity and have detrimental effects on neuroprotection causing neuroinflammation and exacerbation of depression. After a systematic search of literature databases, relevant articles on the microglial regulation of bidirectional neuroimmune pathways affecting neuroplasticity and leading to depression were reviewed. Although, several hypotheses have been proposed for the microglial role in the onset of depression, it is clear that all molecular pathways to depression are linked through microglia-associated neuroinflammation and hippocampal degeneration. Molecular factors such as an excess of glucocorticoids and changes in gene expression of neurotrophic factors, as well as neuro active substances secreted by gut microbiota have also been shown to affect microglial morphology and phenotype resulting in depression. This review aims to critically analyze the various molecular pathways associated with the microglial role in depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.